Sugammadex
Antidotes
Sold as BRIDION
- Drug class
- Antidotes
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 57
Overview
Sugammadex is an active pharmaceutical ingredient in the Antidotes group (V03AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 37 | May 29, 2026 |
| CA Canada | Health Canada | 14 | May 25, 2026 |
| EU European Union | EMA | 6 | February 4, 2026 |
GBUnited Kingdom· MHRA
37 products
Uses
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
For the paediatric population:
Sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
How to take
CACanada· Health Canada
14 products
Uses
Sugammadex Injection (sugammadex sodium) is indicated for: reversal of moderate to deep neuromuscular blockade induced by rocuronium or vecuronium in adult and pediatric patients undergoing surgery. 1 Pediatrics Based on the data submitted and reviewed by Health Canada, the safety and efficacy of sugammadex sodium in pediatric patients, aged birth to 17 years, have been established.
2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with clinically meaningful differences in safety or effectiveness. 4 Geriatrics)
How to take
EUEuropean Union· EMA
6 products
Uses
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years .
How to take
Drug interactions
Known interactions involving Sugammadex. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB445700032 · revised May 29, 2026
- [2]Health Canada (DPD) · 02539144 · revised May 25, 2026
- [3]European Medicines Agency · EMEA/H/C/005935 · revised February 4, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.